BI
BIO.US Bio-Rad Laboratories Inc
- Market cap
- USD 9.85B
- P/E
- 9.7x
- P/B
- 1.31x
- ROE
- 5.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BIO.US undervalued?
Graham numberBIO.US trades 24.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bio-Rad Laboratories Inc fundamental analysis
No fundamental analysis for Bio-Rad Laboratories Inc yet.
Bio-Rad Laboratories Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins…
Full company profileBio-Rad Laboratories Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bio-Rad Laboratories Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.07B | 2.16B | 2.29B | 2.31B | 2.55B | 2.92B | 2.80B | 2.67B | 2.57B | 2.58B | 2.53B |
| Gross Profit | 1.14B | 1.19B | 1.22B | 1.26B | 1.44B | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B | 1.31B |
| Operating Income | 53.2M | 117M | -109M | 230M | 421M | 500M | 483M | 338M | 269M | 271M | 76.0M |
| EBITDA | 206M | 270M | 675M | 2.46B | 5.08B | 5.59B | -4.53B | -655M | -2.14B | 1.21B | 664M |
| Net Income | 28.1M | 115M | 361M | 1.76B | 3.81B | 4.25B | -3.63B | -637M | -1.84B | 760M | 404M |
| EPS | 0.95 | 3.82 | 12 | 58 | 126 | 141 | -122 | -22 | -65 | 28 | 15 |
| Balance Sheet | |||||||||||
| Total Assets | 3.85B | 4.27B | 5.61B | 8.01B | 13.0B | 17.8B | 13.5B | 12.3B | 9.36B | 10.6B | 10.8B |
| Total Liabilities | 1.27B | 1.34B | 1.59B | 2.25B | 3.09B | 4.11B | 3.89B | 3.56B | 2.79B | 3.12B | 3.18B |
| Shareholders' Equity | 2.58B | 2.93B | 4.02B | 5.76B | 9.88B | 13.7B | 9.62B | 8.74B | 6.57B | 7.45B | 7.60B |
| Cash & Short-term Investments | 839M | 755M | 845M | 1.11B | 991M | 870M | 1.79B | 1.61B | 1.66B | 1.54B | 1.66B |
| Total Debt | 435M | 435M | 439M | 651M | 226M | 223M | 1.39B | 1.41B | 1.37B | 1.53B | 1.36B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 216M | 104M | 285M | 458M | 585M | 657M | 194M | 375M | 455M | 532M | 404M |
| Capital Expenditure | 142M | 115M | 130M | 98.5M | 109M | 121M | 114M | 157M | 189M | 158M | 124M |
| Free Cash Flow | 74.5M | -11.0M | 156M | 359M | 476M | 536M | 80.3M | 218M | 266M | 375M | 280M |
| Ratios | |||||||||||
| ROE | 1.1% | 3.9% | 9.0% | 30.6% | 38.6% | 31.1% | -37.7% | -7.3% | -28.1% | 10.2% | 5.3% |
| ROA | 0.7% | 2.7% | 6.4% | 22.0% | 29.4% | 23.9% | -26.9% | -5.2% | -19.7% | 7.2% | 3.7% |
| Net Profit Margin | 1.4% | 5.3% | 15.8% | 76.1% | 149.8% | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% | 15.9% |
| Debt to Equity | 0.17x | 0.15x | 0.11x | 0.11x | 0.02x | 0.02x | 0.14x | 0.16x | 0.21x | 0.21x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bio-Rad Laboratories Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 100B | 3,427 | - |
| 2022 | USD 68.2B | 2,289 | - |
| 2021 | USD 35.3B | 1,168 | 829.3% |
| 2020 | USD 20.2M | 0.67 | 0.5% |
| 2019 | USD 3.83B | 127 | 217.8% |
| 2018 | - | - | - |
| 2017 | USD 4.37M | 0.15 | 3.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Mar 8, 2002.
Who owns Bio-Rad Laboratories Inc
- Insiders 16.29%
- Institutions 83.71%
- Public & others 0.00%
- Shares outstanding 21.8M
- Free float 21.5M
Top funds holding BIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| First Eagle Global A | 1.77M | 6.59% | -5.70% | Sep 2026 |
| American Funds SMALLCAP World A | 931K | 3.46% | +5.58% | Sep 2026 |
| iShares Core S&P Mid-Cap ETF | 655K | 2.43% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 588K | 2.19% | +0.29% | Sep 2026 |
| Vanguard Small Cap Index | 415K | 1.54% | -2.32% | Sep 2026 |
| DFA U.S. Small Cap Value I | 411K | 1.53% | +40.91% | Sep 2026 |
| Ariel Fund Investor | 338K | 1.26% | -3.17% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 270K | 1.00% | +0.17% | Sep 2026 |
| First Eagle Amundi International AU-C | 229K | 0.85% | -5.23% | Sep 2026 |
| FPA Crescent | 175K | 0.65% | -28.23% | Sep 2026 |
| Neuberger Genesis Inv | 145K | 0.54% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 135K | 0.50% | +2.21% | Sep 2026 |
| Fidelity Value | 130K | 0.48% | 0.00% | Sep 2026 |
| Victory Sycamore Small Company Opp R | 124K | 0.46% | +65.33% | Sep 2026 |
| Eaton Vance Atlanta Capital SMID-Cap I | 120K | 0.45% | 0.00% | Sep 2026 |
| Dimensional US Small Cap Value ETF | 120K | 0.44% | 0.00% | Sep 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 99.0K | 0.37% | +0.05% | Oct 2026 |
| Fidelity Extended Market Index | 83.9K | 0.31% | -5.03% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 77.5K | 0.29% | -0.05% | Oct 2026 |
| First Eagle Global Equity ETF | 76.9K | 0.29% | +0.61% | Oct 2026 |
Top institutions holding BIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Arnhold & S. Bleichroeder Advisers, LLC | 5.21M | 19.38% | +100.26% | Jun 2026 |
| BlackRock Inc | 1.70M | 6.32% | +1.12% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 886K | 3.29% | -6.20% | Sep 2026 |
| Vanguard Capital Management, LLC | 827K | 3.08% | -0.50% | Jun 2026 |
| Ariel Investments, LLC | 817K | 3.04% | +3.92% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 816K | 3.04% | -1.57% | Jun 2026 |
| Earnest Partners LLC | 581K | 2.16% | -1.36% | Jun 2026 |
| State Street Corp | 572K | 2.13% | +2.18% | Jun 2026 |
| Bank of America Corp | 490K | 1.82% | +10.22% | Jun 2026 |
| Assenagon Asset Management SA | 466K | 1.73% | +215.53% | Jun 2026 |
| Capital World Investors | 462K | 1.72% | +2.77% | Jun 2026 |
| Capital Research Global Investors | 443K | 1.65% | +15.02% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 419K | 1.56% | -1.68% | Jun 2026 |
| First Pacific Advisors, LP | 402K | 1.49% | -1.35% | Jun 2026 |
| Geode Capital Management, LLC | 348K | 1.29% | -4.69% | Jun 2026 |
| Nomura Holdings Inc | 329K | 1.22% | +51.33% | Jun 2026 |
| UBS Group AG | 308K | 1.15% | -12.99% | Jun 2026 |
| SEI Investments Co | 273K | 1.02% | -5.05% | Jun 2026 |
| Barclays PLC | 268K | 1.00% | -4.02% | Jun 2026 |
| Deerfield Management Co | 226K | 0.84% | 0.00% | Jun 2026 |
Bio-Rad Laboratories Inc company profile
- Company name
- Bio-Rad Laboratories Inc
- Ticker
- BIO.US
- Exchange
- USA Stocks
- Listed since
- Jan 1, 1966
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 7,450
- Fiscal year end
- December
- Address
- 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547
- Phone
- 510 724 7000
- Website
- bio-rad.com
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Bio-Rad Laboratories Inc management
10- Mr. Norman D. SchwartzChairman & CEO · born 1950
- Mr. Jonathan P. DiVincenzoPresident & COO · born 1966
- Mr. Roop K. Lakkaraju CPAExecutive VP & CFO · born 1971
- Mr. James J. BarryExecutive VP & President of Life Science Group · born 1978
- Mr. Rajat MehtaExecutive Vice President of Global Commercial Operations · born 1979
- Mr. Ruben ArguetaVice President of Investor Relations
- Matthew WernerSenior VP and Chief Compliance & Privacy Officer
- Ms. Courtney C. EnloeExecutive VP, General Counsel & Secretary · born 1972
- Ms. Nanditha R. YelamanchiExecutive Vice President of Global Human Resources
- Mr. Michael CrowleyExecutive Vice President of Global Commercial Operations · born 1962